LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Investments Strengthen Biotechnology Cooperation

By LabMedica International staff writers
Posted on 16 Dec 2013
Print article
A series of new investments and cooperative agreements have strengthened the cooperation between a large Swiss/German corporation and a group of Israeli start-up biotechnology companies.

The Merck Serono (Geneva, Switzerland) Israel bioincubator complex in Yavne is set to receive two start-up biotechnology companies, Metabomed Ltd. and ChanBio Ltd. They will be joining Neviah Genomics Ltd., the first company to join the incubator, in which Merck Serono invested 10 million euros.

Metabomed is conducting research on cancer metabolism and computational biology while ChanBio will concentrate on the discovery of selective antibodies for ion channels as possible therapeutic targets for the treatment of multiple sclerosis.

Neviah Genomics was established in June 2012 by Compugen (Tel Aviv, Israel) and Merck Serono. Neviah Genomics focuses on the discovery and development of novel biomarkers for the prediction of drug-induced toxicity. Merck Serono Ventures is providing the initial funding for Neviah Genomics and it will contribute its expertise in the validation and development of biomarkers for the development of a diagnostic test. Compugen will utilize certain proprietary predictive discovery technologies and receive an equity ownership in the new company and a right to royalties from potential future sales.

Separately, Merck Serano's parent company Merck KgaA (Darmstadt, Germany) recently raised its stake in Qlight Nanotech (Jerusalem, Israel). Qlight Nanotech develops semiconductor nanocrystals that display unique optical and electrical properties. Qlight’s nanocrystals enable light conversion from UV and blue wavelengths to any other wavelength in the visible range. The color, or the wavelength, of the light is determined by the nanoparticle's size.

In addition, Merck signed a memorandum of understanding with Kadimastem Ltd. (Nes-Ziona, Israel), a developer of human pluripotent stem cell-related products, to utilize its screening platform to characterize new compounds for remyelinating agents for multiple sclerosis, and which may also help to treat amyotrophic lateral sclerosis (ALS).

"The innovative landscape of Israel fits in perfectly with our "Living Innovation" claim," said Stefan Oschmann head of pharmaceuticals at Merck. “In Israel, we not only have a past which has led to some of Merck’s most important products like Rebif and Erbitux, but also a promising future because we continue to find very interesting and cutting-edge science and the support here in Israel to translate that science into products. Israel has a quality education system and above-average intellectual capital. Compared with other countries, Israel has the highest concentration of scientists and engineers in the world. In addition, cooperation partners appreciate that Israeli scientists often work in a less conventional manner and are faster at implementing their results."

Related Links:

Merck Serono
Compugen
Qlight Nanotech



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more